Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Tadalafil vs Vardenafil (Levitra): they're closely matched on evidence (3 vs 3.6/10); take care combining them — there's a flagged interaction. Take the 60-second quiz for a pick tailored to your goals.
Tadalafil and Vardenafil (Levitra) are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Tadalafil and Vardenafil (Levitra) have evidence — compare verdict strength side-by-side.
Off-label longevity/vascular use mirrors low approved dosing (e.g. tadalafil 2.5–5 mg once daily, the dose used for BPH/daily ED) under a clinician. Not an approved longevity regimen.
any
Low daily-dose oral tablet
Approved on-demand ED dosing is 5-20 mg taken ~30-60 minutes before activity (10 mg typical start for the film-coated tablet); the orodispersible Staxyn tablet is 10 mg. Any use is clinician-directed and prescription-only; this is not a supplement regimen.
any
Oral film-coated tablet (vardenafil HCl)
and 1 more not shown
Additive hypotension, dizziness and syncope; a raised risk of priapism, and of a dangerous fall in blood pressure if a nitrate is ever needed acutely.
Never combine. There is no additive benefit — switching between PDE5 inhibitors means stopping one before starting the other, and any change should go through the prescriber.
Years
Years
Acute to weeks
With interacting drugs
Acute (~30-60 min onset)
Weeks
Acute (per dose)
With interacting drugs / at-risk patients
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.
Heart (British Cardiac Society) (2016) · Observational
Observational cohort of PDE5-inhibitor use in type-2 diabetics at high cardiovascular risk
Using Big Data to Uncover Association Between Sildenafil Use and Reduced Risk of Alzheimer's Disease.
Studies in health technology and informatics (2023) · Observational
Large real-world database study linking PDE5-inhibitor use to lower Alzheimer's incidence
Cardiovascular outcomes among sildenafil users: results of the International Men's Health Study.
International journal of clinical practice (2008) · Observational
⚠️ SILDENAFIL, NOT TADALAFIL. The registry followed sildenafil users. Both are PDE5 inhibitors and the cardiovascular question is a class question, but tadalafil's longer half-life and different selectivity mean this is not a tadalafil outcome.
The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial.
International Journal of Impotence Research (2001) · Rct
Multicentre, randomized, double-blind, placebo-controlled at-home trial in 601 men with mild-to-severe erectile dysfunction
Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study.
Diabetes Care (2003) · Rct
Prospective multicenter double-blind placebo-controlled fixed-dose RCT in men with diabetes and erectile dysfunction
Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy.
The Journal of Urology (2003) · Rct
Randomized, double-blind, placebo-controlled trial in men with erectile dysfunction after radical retropubic prostatectomy
Both Tadalafil and Vardenafil (Levitra) are closely matched — the best choice depends on your specific health goals.
For libido & male vitality, Vardenafil (Levitra) has a higher relevance score (55 vs 52).
Caution: Additive hypotension, dizziness and syncope; a raised risk of priapism, and of a dangerous fall in blood pressure if a nitrate is ever needed acutely. Never combine. There is no additive benefit — switching between PDE5 inhibitors means stopping one before starting the other, and any change should go through the prescriber. Always consult a healthcare provider before combining these supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.